Literature DB >> 2253673

Bioinequivalence of marketed diltiazem preparations.

M V Joshi1, P C Gokhale, S M Pohujani, S S Dalvi, S M Karandikar, N A Kshirsagar.   

Abstract

A bioequivalence study of three brands of regular diltiazem--Angizem (A), Dilzem (B) and Herbesser (C) has been carried out in 5 healthy, male volunteers. After a single oral dose of 60 mg of each preparation, the mean AUC (0-8 h) and Cmax of preparation B was significantly higher than of brands A and C. The tmax of A and B was significantly lower than of C. B had a higher dissolution rate in vitro (98.8% dissolved in 45 min) than A and C. Thus, there was bioinequivalence of the three brands of diltiazem, due partly to differences in dissolution and perhaps in part to a first pass effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253673     DOI: 10.1007/bf00280058

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  3 in total

1.  High-performance liquid chromatographic determination of diltiazem and its major metabolites, N-monodemethyldiltiazem and desacetyldiltiazem, in plasma.

Authors:  S C Montamat; D R Abernethy; J R Mitchell
Journal:  J Chromatogr       Date:  1987-03-20

2.  Pharmacokinetic and pharmacodynamic effects of diltiazem.

Authors:  M S Smith; C P Verghese; D G Shand; E L Pritchett
Journal:  Am J Cardiol       Date:  1983-05-01       Impact factor: 2.778

3.  The pharmacokinetics of diltiazem in healthy American men.

Authors:  R F Zelis; E L Kinney
Journal:  Am J Cardiol       Date:  1982-02-18       Impact factor: 2.778

  3 in total
  3 in total

Review 1.  [Original brands and generic preparations].

Authors:  K U Petersen
Journal:  Med Klin (Munich)       Date:  2000-01-15

Review 2.  Generic drugs. Therapeutic equivalence.

Authors:  P A Meredith
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

3.  Bioinequivalence and drug toxicity. How great is the problem and what can be done?

Authors:  C H Gleiter; U Gundert-Remy
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.